» Articles » PMID: 25629390

Survival Benefit of Solid-organ Transplant in the United States

Overview
Journal JAMA Surg
Specialty General Surgery
Date 2015 Jan 29
PMID 25629390
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: The field of transplantation has made tremendous progress since the first successful kidney transplant in 1954.

Objective: To determine the survival benefit of solid-organ transplant as recorded during a 25-year study period in the United Network for Organ Sharing (UNOS) database and the Social Security Administration Death Master File.

Design, Setting, And Participants: In this retrospective analysis of UNOS data for solid-organ transplant during a 25-year period (September 1, 1987, through December 31, 2012), we reviewed the records of 1,112,835 patients: 533,329 recipients who underwent a transplant and 579 506 patients who were placed on the waiting list but did not undergo a transplant.

Main Outcomes And Measures: The primary outcome was patient death while on the waiting list or after transplant. Kaplan-Meier survival functions were used for time-to-event analysis.

Results: We found that 2,270,859 life-years (2,150,200 life-years from the matched analysis) were saved to date during the 25 years of solid-organ transplant. A mean of 4.3 life-years were saved (observed to date) per solid-organ transplant recipient. Kidney transplant saved 1,372,969 life-years; liver transplant, 465,296 life-years; heart transplant, 269,715 life-years; lung transplant, 64,575 life-years; pancreas-kidney transplant, 79,198 life-years; pancreas transplant, 14,903 life-years; and intestine transplant, 4402 life-years.

Conclusions And Relevance: Our analysis demonstrated that more than 2 million life-years were saved to date by solid-organ transplants during a 25-year study period. Transplants should be supported and organ donation encouraged.

Citing Articles

Extracellular Vesicles as Biomarkers in Infectious Diseases.

Cruz C, Sodawalla H, Mohanakumar T, Bansal S Biology (Basel). 2025; 14(2).

PMID: 40001950 PMC: 11851951. DOI: 10.3390/biology14020182.


CD34 PI16 fibroblast progenitors aggravate neointimal lesions of allograft arteries via CCL11/CCR3-PI3K/AKT pathway.

Xu X, Zhu P, Wang H, Chen K, Liu L, Du L Theranostics. 2025; 15(6):2523-2543.

PMID: 39990233 PMC: 11840720. DOI: 10.7150/thno.104650.


Second kidney transplant during childhood: clinical aspects, outcomes, and risk factors for graft survival.

de Santis Feltran L, Hamamoto F, Genzani C, Fonseca M, de Carvalho M, Koch-Nogueira P Pediatr Nephrol. 2025; .

PMID: 39954072 DOI: 10.1007/s00467-025-06685-6.


Evaluating Graft Loss Risk in Living-Donor Kidney Transplants with Multiple Renal Arteries.

Inoue K, Hori S, Tomizawa M, Yoneda T, Nakai Y, Miyake M Ann Transplant. 2025; 29():e946489.

PMID: 39801158 PMC: 11699694. DOI: 10.12659/AOT.946489.


Targeting T helper 17 cells: emerging strategies for overcoming transplant rejection.

Lee Y, Cho M Clin Transplant Res. 2025; 38(4):309-325.

PMID: 39743231 PMC: 11732763. DOI: 10.4285/ctr.24.0058.